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Abstract: Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), although initially developed as glucose-lowering drugs, provide
significant beneficial effects on cardiorenal outcomes, including heart failure, regardless of type 2
diabetes status. Integration of SGLT-2is into clinical practice requires practical guidance for physicians
about their use. To overcome physicians’ clinical inertia for SGLT-2i use, including addressing safety,
potentially a barrier to their use, a roundtable discussion with physicians from three specialties
(cardiology, endocrinology, and nephrology) was conducted. This review summarizes the physicians’
clinical experience and recommendations about SGLT-2i use across different patient populations,
taking into consideration the beneficial effects of SGLT-2is and their safety. The key aspects discussed
regarding SGLT-2i safety include acute effects on kidney function (estimated glomerular filtration rate
acute dip upon SGLT-2i initiation and acute kidney injury), volume depletion, diabetic ketoacidosis,
genitourinary infections, hyperkalemia, and hypoglycemia. To mitigate any potential risks related to
SGLT-2i safety, physicians can make minor adjustments to an individual patient’s treatment plan,
while retaining the SGLT-2i cardiorenal benefits for effective disease management. Recognition by
physicians that the benefits of SGLT-2i use on clinical outcomes outweigh the risks will result in the
integration of SGLT-2is into clinical practice and lead to improved patient care and outcomes.
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1. Introduction
There has been an increased awareness among physicians about the beneficial effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2is) [1], originally developed as
glucose-lowering agents, on cardiovascular (CV) and renal outcomes (independent of their
glycemic effects), which has been driven in part by clinical trial evidence and practice
guideline updates [2,3]. Consequently, it is important that physicians are aware of SGLT-2is’
mechanism of action and their potential to improve patients’ outcomes, while considering
the potential for adverse effects, and of how to best integrate SGLT-2is into their clinical
practice, as a means to better address the individual patient’s therapeutic goals. This article
provides an overview of the CV and renal benefits of SGLT-2is in patients with and without
type 2 diabetes (T2D) and addresses the potential physician-related barriers to the effective
use of these drugs in routine clinical practice, including aspects related to safety that may
contribute to clinical inertia.
2. SGLT-2is
The first SGLT-2i, phlorizin, a plant-based glycoside of the flavonoid group, was
discovered 150 years ago. Phlorizin was not a viable therapeutic agent, because it had poor
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oral absorption, lacked specificity, and had severe side effects in animal models [4–6]. Selective SGLT-2is were first reported in the 1990s, followed by the development of canagliflozin,
dapagliflozin, empagliflozin, and ertugliflozin [6]. In 2008, the US Food and Drug Administration (FDA) mandated that CV outcome trials (CVOTs) for novel antidiabetic agents be
conducted [7] to show that glucose-lowering agents do not carry excess CV risk. Consequently, CVOTs in patients with T2D and established atherosclerotic CV disease (ASCVD)
or high CV risk (EMPA-REG OUTCOME, CANVAS, DECLARE–TIMI 58, and VERTIS CV)
were conducted for several SGLT-2is [8–11]. Figure 1 shows SGLT-2i development leading
up to approvals for different indications. The chemical structures of the four SGLT-2is with
US FDA approval are presented in Supplementary Figure S1.
SGLT-2is act by blocking the paired reuptake of sodium and glucose in the renal
proximal tubule, thereby promoting urinary glucose and sodium excretion [2]. Reduction
in glucose reabsorption in the kidney and lowering of plasma glucose are independent
of insulin levels or peripheral insulin resistance [5,12]. Apart from glycemic control, the
beneficial effects of SGLT-2is encompass weight loss (glucosuria-induced energy loss) and
small blood pressure (BP) reduction (due to osmotic diuresis and intravascular volume
contraction) [13]. Delivery of sodium to the distal tubule increases tubuloglomerular
feedback and reduces intraglomerular pressure [14–17]. Combined with osmotic diuresis,
this leads to a reduction in volume overload, reduced blood pressure, and lower preload
and afterload, which may preserve renal function and have beneficial effects on cardiac
remodeling [14,15,18]. Figure 2 shows the mechanisms of action for SGLT-2is.
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Table 1. Summary of glycemic, cardiovascular, and renal end points in the SGLT-2i outcome trials.
Scheme 1

Population

Median Follow-Up

HbA1c Difference vs. Placebo,
Mean (95% CI)

CV Outcomes,
HR (95% CI)

Renal Outcomes,
HR (95% CI)

−0.58% (−0.61%, −0.56%)

MACE a : 0.86 (0.75–0.97); p < 0.001 for
noninferiority and p = 0.02 for superiority
CV death or HHF:
0.78 (0.67–0.91)
HHF: 0.67 (0.52–0.87)
CV death: 0.87 (0.72–1.06)

Progression of albuminuria:
0.73 (0.67–0.79)
40% reduction in eGFR, RRT
initiation, or death from renal
causes:
0.60 (0.47–0.77)

−0.25% (−0.31%, −0.20%)

MACE a : 0.80 (0.67–0.95); p = 0.01
CV death or HHF:
0.69 (0.57–0.83)
p < 0.001
HHF: 0.61 (0.47–0.80)
p < 0.001
CV death: 0.78 (0.61–1.00); p = 0.05

ESKD, doubling of sCr, or death
from renal causes: 0.66
(0.53–0.81); p < 0.001
Doubling of sCr:
0.60 (0.48–0.76); p < 0.001
ESKD: 0.68 (0.54–0.86); p = 0.002

−0.42% (−0.45%, −0.40%)

MACE a : 0.93 (0.84–1.03); p < 0.001 for
noninferiority and p = 0.17 for superiority
CV death or HHF:
0.83 (0.84–0.95); p = 0.005
HHF: 0.73 (0.61–0.88)
CV death: 0.98 (0.82–1.17)

≥40% reduction in eGFR to <60
mL/min/1.73 m2 , ESKD, or
death from CV or renal causes:
0.76 (0.67–0.87)
≥40% reduction in eGFR to <60
mL/min/1.73 m2 , ESKD, or
death from renal causes: 0.53
(0.43–0.66)

−0.24% (−0.34%, −0.13%); p <
0.001 c

Worsening HF d or CV death: 0.74
(0.65–0.85); p < 0.001
CV death or HHF:
0.75 (0.65–0.85); p < 0.001
Worsening HF d :
0.70 (0.59–0.83)
HHF: 0.70 (0.59–0.83)
Urgent HF visit:
0.43 (0.20–0.90)
CV death: 0.82 (0.69–0.98)

Worsening renal function e : 0.71
(0.44–1.16)

Canagliflozin

CANVAS [9]

CREDENCE [22]

Age ≥ 30 y with T2D and
established CVD
OR
Age ≥ 50 y with T2D and ≥2
CVD risk factors (n = 10,142)

Age ≥30 y with T2D and CKD b
(n = 4401)

~126 wk

~2.6 y

Dapagliflozin

DECLARE–TIMI 58 [10]

DAPA-HF [23]

Age ≥ 40 y with T2D and
established CVD
OR
Age ≥ 55 y (men) or ≥60 y
(women) with T2D and ≥1 CVD
risk factor (n = 17,160)

Age ≥18 y with NYHA class
II–IV HFrEF (EF ≤40%) with or
without T2D (n = 4744)

4.2 y

18.2 mo
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Table 1. Cont.
Scheme 1

DAPA-CKD [21]

Population

Age ≥18 y with CKD f with or
without T2D (n = 4094)

Median Follow-Up

2.4 y

HbA1c Difference vs. Placebo,
Mean (95% CI)

CV Outcomes,
HR (95% CI)

Renal Outcomes,
HR (95% CI)

NR

CV death or HHF:
0.71 (0.55–0.92); p = 0.009
CV death: 0.81 (0.58–1.12)

Sustained ≥50% reduction in
eGFR, ESKD, or death from CV
or renal causes: 0.61 (0.51–0.72);
p < 0.001
Sustained ≥50% reduction in
eGFR, ESKD, or death from renal
causes: 0.56 (0.45–0.68); p < 0.001
≥ 50% reduction in eGFR: 0.53
(0.42–0.67)
ESKD: 0.64 (0.50–0.82)

MACE a : 0.86 (0.74–0.99); p < 0.001 for
noninferiority and p = 0.04 for superiority
MACE a or hospitalization for UA: 0.89
(0.78–1.01); p < 0.001 for noninferiority
and p = 0.08 for superiority
CV death or HHF: 0.66 (0.55–0.79); p <
0.001
HHF: 0.65 (0.50–0.85); p = 0.002
CV death: 0.62 (0.49–0.77); p < 0.001

Incident or worsening
nephropathy g : 0.61 (0.53–0.70);
p < 0.001
Doubling of sCr with eGFR ≤45
mL/min/1.73 m2 , RRT initiation,
or death from renal causes:
0.54 (0.40–0.75); p < 0.001

Empagliflozin

EMPA-REG OUTCOME [11,24]

Age ≥18 y with T2D and
established CVD (n = 7020)

3.1 y

Adjusted mean difference, 10 mg
dose: −0.24% (−0.40%, −0.08%);
25 mg dose: −0.36% (−0.51%,
−0.20%)

EMPEROR-Reduced [25]

Age ≥18 y with NYHA class
II–IV HFrEF (EF ≤40%) with or
without T2D (n = 3730)

16 mo

Absolute difference:
−0.16 (−0.25, −0.08) c

CV death or HHF:
0.75 (0.65–0.86); p < 0.001
HHF: 0.69 (0.59–0.81)
CV death: 0.92 (0.75–1.12)

Composite renal outcome h : 0.50
(0.32–0.77)

Adjusted mean difference:
−0.19% (−0.25%, −0.14%)c

CV death or HHF:
0.79 (0.69–0.90); p < 0.001
HHF: 0.71 (0.60–0.83)
CV death: 0.91 (0.76–1.09)

Mean difference (95% CI) in
eGFR slope change per year vs.
placebo: 1.36 (1.06–1.66)
mL/min/1.73 m2 ; p < 0.001
Composite renal outcome h : 0.95
(0.73–1.24)

EMPEROR-Preserved [26]

Age ≥18 y with NYHA class
II–IV HFpEF (EF >40%) with or
without T2D (n = 5988)

26.2 mo
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Table 1. Cont.
Scheme 1

Population

Median Follow-Up

HbA1c Difference vs. Placebo,
Mean (95% CI)

CV Outcomes,
HR (95% CI)

Renal Outcomes,
HR (95% CI)

3.0 y

LSM difference at wk 18 vs.
baseline, 5 mg: −0.70% (−0.73%,
−0.67%); 15 mg: −0.72%
(−0.75%, −0.69%); placebo:
−0.22% (−0.25%, −0.19%)

MACE: 0.97 (0.85–1.11); p < 0.001 for
noninferiority
CV death or HHF:
0.88 (0.75–1.03); p = 0.11
HHF: 0.70 (0.54–0.90)
CV death: 0.92 (0.77–1.11)

Doubling of sCr, RRT initiation,
or death from renal causes: 0.81
(0.63–1.04)

Ertugliflozin

Age ≥40 y with T2D and
established CVD (n = 8246)

VERTIS CV [8]

a

Defined as the composite outcome of CV death, nonfatal myocardial infarction, or nonfatal stroke. b Defined as an eGFR of 30 –< 90 mL/min/1.73 m2 and a UACR of >300–5000 mg/g.
In patients with diabetes. d Defined as hospitalization or an urgent visit resulting in intravenous therapy for HF. e Defined as the composite outcome of ≥50% reduction in eGFR
sustained for ≥28 days, ESKD, or death from renal causes. f Defined as an eGFR of 25–75 mL/min/1.73 m2 and a UACR of 200–5000 mg/g. g Defined as the composite outcome of
progression to macroalbuminuria (UACR >300 mg/g), doubling of sCr accompanied by an eGFR of ≤45 mL/min/1.73 m2 , initiation of RRT, or death from renal causes. h Defined as
long-term dialysis or renal transplantation, a sustained reduction of ≥40% in eGFR, or a sustained eGFR of <15 mL/min/1.73 m2 (in those with baseline eGFR of ≥30 mL/min/1.73 m2 )
or <10 mL/min/1.73 m2 (in those with baseline eGFR of <30 mL/min/1.73 m2 ). CI, confidence interval; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease;
eGFR, estimated glomerular filtration rate; EF, ejection fraction; ESKD, end-stage kidney disease; HbA1c, glycated hemoglobin; HF, heart failure; HFpEF, HF with preserved ejection
fraction; HFrEF, HF with reduced ejection fraction; HHF, hospitalization for HF; HR, hazard ratio; LSM, least squares mean; MACE, major adverse cardiovascular events; NR, not
reported; NYHA, New York Heart Association; RRT, renal replacement therapy; sCr, serum creatinine; SGLT-2i, sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes; UA,
unstable angina; UACR, urinary albumin-to-creatinine ratio.
c
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The clinical evidence from these outcome trials, demonstrating the cardio- and renoprotective benefits of SGLT-2is in patients with or without T2D, has led to the expansion
of the FDA-approved indications (ASCVD, CKD, CV disease (CVD), and/or HF with
reduced ejection fraction (HFrEF) or with preserved ejection fraction (HFpEF)) for SGLT-2is
(Figure 1) [27–29]. Clinical practice guidelines have also been updated to include SGLT-2i
therapy for the prevention of CV and renal complications (Table 2) [30–37].
Table 2. Guidelines for the use of SGLT-2is.
Year

Guidelines

SGLT-2is

2019

American College of Cardiology
(ACC)/American Heart Association (AHA) [33]

Canagliflozin, dapagliflozin, and
empagliflozin
Canagliflozin, dapagliflozin, and
empagliflozin

Indications
T2D and ASCVD

2019

European Society of Cardiology (ESC) [34]

2020

Kidney Disease: Improving Global Outcomes
(KDIGO) Clinical Practice Guideline for Diabetes
Management in Chronic Kidney Disease [35]

2021

ESC/Heart Failure Association (HFA) of the ESC
[37]

2021

ACC Expert Consensus Decision Pathway for
Optimization of Heart Failure Treatment [36]

Dapagliflozin and a empagliflozin a

HFrEF with or without T2D

American Diabetes Association [31,32]

SGLT-2i drug class recommended
An SGLT-2i with proven benefit for the
individual patient’s comorbidities is
recommended (CVD: canagliflozin,
dapagliflozin, empagliflozin, and
ertugliflozin; DKD: canagliflozin,
dapagliflozin, and empagliflozin)

T2D, ASCVD, HF, and DKD

2022

Canagliflozin, dapagliflozin, and
empagliflozin
Canagliflozin, dapagliflozin,
empagliflozin, ertugliflozin, and
sotagliflozin
Dapagliflozin, empagliflozin, and
sotagliflozin

T2D and CVD
T2D and CKD

T2D and CVD
T2D and HFrEF

a

Prescribed in conjunction with a background of guideline-directed medical therapy for HF. ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DKD, diabetic kidney
disease; HF, heart failure; HFrEF, HF with reduced ejection fraction; SGLT-2i, sodium-glucose cotransporter-2
inhibitor; T2D, type 2 diabetes.

For optimal prescribing of SGLT-2is, a complete understanding of the potential risks
associated with their use, in addition to their benefits, is required. Table 3 summarizes
the safety profiles of SGLT-2is in patients with T2D and established CVD or high CVD
risk, with T2D and CKD, with HF with or without T2D, and with CKD with or without T2D [8–11,21–26]. Among physicians, the key safety considerations that may prevent
prescription of SGLT-2is are volume depletion and associated acute kidney injury (AKI),
hypoglycemia, diabetic ketoacidosis (DKA), and genitourinary infections [27–29,38]; however, adverse events with SGLT-2is are generally manageable, and serious adverse events
are rare [12]. Adverse effects can be mitigated by making minor adjustments tailored to
meet specific patient requirements for effective disease management and/or to address
intermittent illness or major surgery (“sick-day” strategy) [39].
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Table 3. Summary of safety results from the SGLT-2i outcome trials.
Study Name

Population

Risk of AEs

Age ≥30 y with T2D and established CVD
OR
Age ≥50 y with T2D and ≥2 CVD risk factors
(n = 10,142)

•
•
•

Any SAE (vs. placebo): HR, 0.93 (95% CI, 0.87–1.00); p = 0.04
AE leading to discontinuation (vs. placebo): HR, 1.13 (95% CI, 0.99–1.28); p = 0.07
Higher rate vs. placebo of amputation (p < 0.001), adjudicated fracture (p = 0.02), infection of male genitalia
(p < 0.001), osmotic diuresis (p < 0.001), volume depletion (p = 0.009), and mycotic genital infection in
women (p < 0.001)

•
•
•
•
•

Any AE (vs. placebo): HR, 0.87 (95% CI, 0.82–0.93)
Any SAE (vs. placebo): HR, 0.87 (95% CI, 0.79–0.97)
Treatment-related SAEs (vs. placebo): HR, 1.45 (95% CI, 0.98–2.14)
Higher risk vs. placebo of diabetic ketoacidosis (HR, 10.80 (95% CI, 1.39–83.65))
Similar risk vs. placebo of lower extremity amputation (HR, 1.11 (95% CI, 0.79–1.56)) and fracture (HR,
0.98 (95% CI, 0.70–1.37))

•
•
•
•

Any SAE (vs. placebo): HR, 0.91 (95% CI, 0.87–0.96); p < 0.001
AE leading to discontinuation (vs. placebo): HR, 1.15 (95% CI, 1.03–1.28); p = 0.01
Lower risk vs. placebo of major hypoglycemic event (HR, 0.68; p = 0.02) and AKI (HR, 0.69; p = 0.002)
Higher risk vs. placebo of diabetic ketoacidosis (HR, 2.18; p = 0.02) and genital infection (HR, 8.36;
p < 0.001)
Similar risk vs. placebo of amputation (HR, 1.09; p = 0.53), fracture (HR, 1.04; p = 0.59), volume depletion
symptoms (HR, 1.00; p = 0.99), and UTI (HR, 0.93; p = 0.54)

Canagliflozin

CANVAS [9]

CREDENCE [22]

Age ≥30 y with T2D and CKD a (n = 4401)

Dapagliflozin

DECLARE–TIMI 58 [10]

DAPA-HF [23]

DAPA-CKD [21]

Age ≥40 y with T2D and established CVD
OR
Age ≥55 y (men) or ≥60 y (women) with T2D and ≥1 CVD risk
factor (n = 17,160)

Age ≥18 y with NYHA class II–IV HFrEF (EF ≤ 40%) with or
without T2D (n = 4744)

Age ≥18 y with CKD b with or without T2D
(n = 4094)

•
•
•
•
•

Any SAE (vs. placebo): 37.8% vs. 42.0%
AE leading to discontinuation (vs. placebo): 4.7% vs. 4.9%; p = 0.79
Lower incidence vs. placebo of serious renal events (1.6% vs. 2.7%; p = 0.009)
Similar incidence vs. placebo of SAEs related to volume depletion (1.2% vs. 1.7%; p = 0.23)

•
•
•
•
•

Any SAE (vs. placebo): 29.5% vs. 33.9%; p = 0.002
AE leading to discontinuation (vs. placebo): 5.5% vs. 5.7%; p = 0.79
Lower incidence vs. placebo of major hypoglycemia (0.7% vs. 1.3%; p = 0.04)
Higher incidence vs. placebo of volume depletion (5.9% vs. 4.2%; p = 0.01)
Similar incidence vs. placebo of amputation (1.6% vs. 1.8%; p = 0.73), definite or probable diabetic
ketoacidosis (0% vs. <0.1%; p = 0.50), fracture (4.0% vs. 3.2%; p = 0.22), and renal-related AE (7.2% vs. 8.7%;
p = 0.07)
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Table 3. Cont.
Study Name

Population

Risk of AEs

Empagliflozin

•
•
•
EMPA-REG OUTCOME [11]

Age ≥18 y with T2D and established CVD
(n = 7020)

•
•

EMPEROR-Reduced [25]

EMPEROR-Preserved [26]

Age ≥18 y with NYHA class II–IV HFrEF (EF ≤40%) with or
without T2D (n = 3730)

Age ≥18 y with NYHA class II–IV HFpEF
(EF >40%) with or without T2D (n = 5988)

Any SAE (vs. placebo): 38.2% vs. 42.3%; p < 0.001
AE leading to discontinuation (vs. placebo): 17.3% vs. 19.4%; p < 0.01
Lower incidence vs. placebo of UTI in women (36.4% vs. 40.6%; p < 0.05), AKI (1.0% vs. 1.6%; p < 0.05),
and acute renal failure (5.2% vs. 6.6%; p < 0.01)
Higher incidence vs. placebo of genital infection in men (5.0% vs. 1.5%; p < 0.001) and women (10.0% vs.
2.6%; p < 0.001)
Similar incidence vs. placebo of hypoglycemia requiring assistance (1.3% vs. 1.5%), UTI (18.0% vs. 18.1%),
complicated UTI (1.7% vs. 1.8%), volume depletion (5.1% vs. 4.9%), fracture (3.8% vs. 3.9%),
thromboembolic event (0.6% vs. 0.9%), and diabetic ketoacidosis (0.1% vs. <0.1%)

•
•
•

Any SAE (vs. placebo): 41.4% vs. 48.1%
Higher incidence vs. placebo of genital infections (1.7% vs. 0.6%)
Similar incidence vs. placebo of volume depletion (10.6% vs. 9.9%), hypotension (9.4% vs. 8.7%),
symptomatic hypotension (5.7% vs. 5.5%), UTI (4.9% vs. 4.5%), fracture (2.4% vs. 2.3%), hypoglycemic
event (1.4% vs. 1.5%), complicated UTI (1.0% vs. 0.8%), lower extremity amputation (0.7% vs. 0.5%),
complicated genital infection (0.3% vs. 0.3%), and ketoacidosis (0% vs. 0%)

•
•
•

Any SAE (vs. placebo): 47.9% vs. 51.6%
AE leading to discontinuation (vs. placebo): 19.1% vs. 18.4%
Higher incidence vs. placebo of hypotension (10.4% vs. 8.6%), UTI (9.9% vs. 8.1%), and genital infection
(2.2% vs. 0.7%)
Similar incidence vs. placebo of acute renal failure (12.1% vs. 12.8%), symptomatic hypotension (6.6% vs.
5.2%), fracture (4.5% vs. 4.2%), hypoglycemic event (2.4% vs. 2.6%), ketoacidosis (0.1% vs. 0.2%),
complicated UTI (1.9% vs. 1.5%), lower extremity amputation (0.5% vs. 0.8%), and complicated genital
infection (0.3% vs. 0.3%)

•
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Table 3. Cont.
Study Name

Population

Risk of AEs

Ertugliflozin

•
•
•
VERTIS CV [8]

Age ≥40 y with T2D and established CVD
(n = 8246)

•
•

a

Any SAE (vs. placebo): risk difference, 1.2 (95% CI, −3.7, 1.4) (5 mg); −2.0 (95% CI, −4.5, 0.6) (15 mg)
AE leading to discontinuation (vs. placebo): risk difference, 0.7 (95% CI, −0.7, 2.1) (5 mg); 0.5 (95% CI −0.9,
1.8) (15 mg)
Higher risk vs. placebo of UTI (risk difference, 2.1 (p = 0.02; 5 mg); 1.8 (p = 0.03; 15 mg)), genital mycotic
infection in women (risk difference, 3.6 (p < 0.001; 5 mg); 5.4 (p < 0.001; 15 mg)) and men (risk difference,
3.3 (p < 0.001; 5 mg); 4.0 (p < 0.001; 15 mg))
Similar risk vs. placebo of symptomatic hypoglycemia (risk difference, −0.8 (5 mg); −2.3 (15 mg)), severe
hypoglycemia (risk difference, −0.9 (5 mg); −0.5 (15 mg)), hypovolemia (risk difference, 0.4 (5 mg); 0.4
(15 mg)), AKI (risk difference −0.4 (5 mg); −0.3 (15 mg)), and amputation (pooled risk difference, 0.1)
Similar incidence vs. placebo of fractures (3.6% (5 mg) and 3.7% (15 mg) vs. 3.6%), serious AKI (0.9%
(5 mg) and 0.7% (15 mg) vs. 0.8%), and serious UTI (0.9% (5 mg) and 0.4% (15 mg) vs. 0.8%)

Defined as an eGFR of 30 –< 90 mL/min/1.73 m2 and a UACR of >300–5000 mg/g. b Defined as an eGFR of 25–75 mL/min/1.73 m2 and a UACR of 200–5000 mg/g. AE, adverse
event; AKI, acute kidney injury; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; EF, ejection fraction; HF,
heart failure; HFpEF, HF with preserved ejection fraction; HFrEF, HF with reduced ejection fraction; HR, hazard ratio; NYHA, New York Heart Association; SAE, serious AE; SGLT-2i,
sodium-glucose cotransporter-2 inhibitor; T2D, type 2 diabetes; UACR, urinary albumin-to-creatinine ratio; UTI, urinary tract infection.
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3. Overcoming Physician-Related Barriers to SGLT-2i Use
Evidence from several clinical outcome trials has demonstrated the cardio- and renoprotective effects of SGLT-2is in patients with established CVD or at risk for CVD, including
HF or CKD, with or without T2D; however, physicians’ practice and perceptions have
impeded the use of SGLT-2is [3]. To overcome clinical inertia regarding the use of SGLT-2is
in routine clinical practice and to address any key safety aspects associated with SGLT-2is,
a roundtable discussion including physicians from three different specialties (cardiology,
endocrinology, and nephrology) was conducted. This section considers the opinions of
these physicians on key aspects related to the use of SGLT-2is and their clinical experience
across differing patient populations. Their varied treatment approaches are summarized in
Figure 3.
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3.1. Acute Effects on Renal Function upon SGLT-2i Initiation
3.1.1. eGFR Acute Dip
An acute decrease in eGFR of ~2–5 mL/min/1.73 m2 , also known as “eGFR dip”, can
occur within the first 2–4 weeks of SGLT-2i treatment initiation [41–43], but it is typically
followed by a partial recovery of kidney function by week 12 and then an attenuation of
the slope of the decline in eGFR compared with that of placebo [42,44]. An acute eGFR dip
is more likely in patients receiving thiazides and/or loop diuretics at baseline and those
belonging to a higher Kidney Disease: Improving Global Outcomes risk category [42,43].
An initial >10% decrease in eGFR, which does not require that SGLT-2is be discontinued,
has been reported in 25% of patients; eGFR decreases of >30% are rare [42,43], and, in
these patients, SGLT2i therapy should be temporarily discontinued until eGFR returns to
baseline [43]. In patients with lower eGFR (stage 4 CKD; eGFR <30 mL/min/1.73 m2 ),
the eGFR dip is smaller than that observed in patients with stage 2/3 CKD (eGFR ≥30–
≤90 mL/min/1.73 m2 ; 1.42 mL/min/1.73 m2 compared with 2.56 mL/min/1.73 m2 ,
respectively, from baseline to 2 weeks); this indicates that the eGFR dip is attenuated in
patients with stage 4 CKD [45]. In addition, the initial eGFR dip is not associated with
reduced benefit with respect to cardiorenal outcomes [42,45].
On the basis of data from the EMPA-REG OUTCOME [11], DAPA-CKD [21], VERTIS
CV [8], and CREDENCE [22] trials, as well as real-world evidence [46], increased frequency
in monitoring, beyond that indicated by a patient’s diabetes and kidney disease, is not warranted unless there are signs and symptoms of volume depletion (orthostatic hypotension,
BP <120/70 mmHg) in specific patients, such as those who are aged >65–70 years or those
receiving high-dose diuretics [43].
3.1.2. AKI
There may be a perception of an increased risk of AKI with the use of SGLT-2is.
However, the incidence of AKI, defined as a serum creatinine increase of >0.3 mg/dL
(within 48 h) or >1.5 times the baseline value (prior 7 days), is low with SGLT-2is, as
reported in clinical and real-world studies [21,22,47–49]. Although there have been postmarketing reports of AKI with SGLT-2is in association with volume depletion [27–29,38],
clinical trials showed a lower risk of AKI (vs. placebo) with dapagliflozin (serious adverse
events, 1.8% vs. 2.4% of patients) in DAPA-CKD [21] and in DAPA-HF (serious adverse
events, 1.0% vs. 1.9% of patients) [23] and with canagliflozin (adverse events, 16.9 vs.
20.0 events per 1000 patient-years) in CREDENCE [22]. Similarly, the rate of AKI was not
increased compared with that of placebo for empagliflozin, canagliflozin, or dapagliflozin
in EMPA-REG OUTCOME [24], CANVAS [9], and DECLARE–TIMI 58 [10], respectively.
Furthermore, a meta-analysis of 18 trials (n = 156,690) showed that the risk of AKI with
SGLT-2is was 24% lower than that with placebo [50]. An increased risk of AKI with SGLT-2is
was not observed in an observational study of patients from two CKD registries [47] or in a
retrospective study comparing AKI incidence with SGLT-2is and other glucose-lowering
drugs [48]. In a meta-analysis of the CV, HF, and renal outcome trials of SGLT-2is compared
with placebo, the risk for AKI was reduced by 25%, irrespective of the specific SGLT-2i
used, the population included (patients with or without T2D), and the patients’ underlying
kidney disease, diabetes, or HF status [1].
Although AKI rarely occurs with SGLT-2i use [48], renal function should be assessed
prior to the initiation of the SGLT-2i and regularly afterward [36,37,40]. Patients with an
eGFR of <60 mL/min/1.73 m2 at initiation may require more frequent assessment of renal
function because of their underlying CKD rather than their use of an SGLT-2i. In patients
with AKI, SGLT-2i treatment should temporarily be discontinued until renal function
improves [35–37,46].
3.2. Volume Depletion
SGLT-2is cause glucosuria-induced osmotic diuresis and natriuresis, which can result
in a total fluid loss of ~1–2 kg and sodium loss of 6% in the first 1–2 weeks of treatment,
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which subsequently stabilizes [51]. This plasma volume reduction leads to a sustained
lowering of BP by 4–6 mmHg (systolic)/1–2 mmHg (diastolic) [12]. Patients at increased
risk of volume depletion are those with eGFR <60 mL/min/1.73 m2 , those with older age
(≥ 65 years old), and those receiving loop diuretics [28,29]. In general, SGLT-2is are not
hypotensive agents, as the reductions in systolic BP are small in magnitude. However, an
increased risk of volume-depletion-related adverse effects was reported in patients with
HFrEF and baseline systolic BP of <110 mmHg in the DAPA-HF trial [52].
Prior to SGLT-2i initiation, volume depletion can be addressed by a reduction in
the dose of diuretics (based on the individual patient’s volume status) or hypotensioninducing agents (angiotensin-converting enzyme inhibitor and angiotensin II receptor
blocker) [12,39,53]. Although SGLT-2is do not appear to increase the risk of orthostatic
hypotension in randomized controlled trials [54], volume correction is necessary in patients
with volume depletion or existing hypotension to avoid potential orthostatic hypotension
upon initiation of SGLT-2i treatment [39]. After SGLT-2i initiation, close monitoring of
body weight, BP, and volume status is recommended, and patients should be counseled
about avoiding dehydration and the risk of orthostatic hypotension, particularly in the first
week of therapy [12,40,55]. In the event of an acute illness, major surgery, or ingestion of
nothing or a marked reduction in oral intake, SGLT-2i treatment should be temporarily
discontinued until recovery, following the “sick-day” strategy [39,55].
3.3. DKA
Patients with a lack of endogenous insulin (certain insulin-dependent T2D or type
1 diabetes) are at increased risk of DKA, with a higher incidence observed in patients
with type 1 diabetes [39]. An increased risk of non-SGLT-2i-associated DKA has been
attributed to precipitating events including stressful events (i.e., infections, alcohol abuse,
surgery, stroke, myocardial infarction, or trauma), because they increase the production of
counter-regulatory stress hormones such as glucagon, leading to lipolysis and promotion
of ketone formation in the presence of insulin deficiency [56,57]. Although DKA associated
with SGLT-2i use is rare (~0.5 per 1000 patient-years) [12], a meta-analysis indicated that
the risk of DKA may be increased with SGLT-2is compared with that with placebo [58].
DKA associated with SGLT-2i use may be caused by underlying insulin insufficiency, an
increased rate of fatty acid oxidation, reduced ketone clearance, or stimulation of glucagon
secretion [59].
The usual symptoms of DKA are nausea, vomiting, malaise, abdominal pain, and
fruity odor on the breath [12,39]. In patients receiving SGLT-2is, the diagnosis of DKA can
be delayed because blood glucose may be normal or only slightly elevated (i.e., euglycemic
DKA), as opposed to classic DKA in which the patients have hyperglycemia [56]. Therefore,
assessment of serum ketones or urine ketones is needed in patients receiving SGLT-2is who
present with DKA symptoms and slightly elevated blood glucose [60]. DKA is usually
treated with insulin and fluid and electrolyte replacement [39]. When initiating SGLT-2i
treatment in a patient receiving insulin and considering a reduction in insulin dosage,
initial reductions of >20% should be avoided to prevent triggering DKA [40]. In patients
with acute illness or 3 days before a major surgery, the “sick-day” strategy should be
considered, whereby SGLT-2i treatment is temporarily discontinued to minimize the risk of
DKA [36,40]. SGLT-2i therapy should also be stopped in patients who are not following
a proper diet and/or in those who are inadequately hydrated. Moreover, factors in the
patient history that may predispose to ketoacidosis should be considered before starting
SGLT-2i therapy [2,12,39]. There is no evidence of ketoacidosis with SGLT-2is in patients
without T2D [21,23]. Therefore, the physicians agreed that, if indicated, SGLT-2is can be
prescribed without hesitation to patients with HF or CKD who do not have T2D.
3.4. Genital Mycotic Infections, Urinary Tract Infections, and Fournier’s Gangrene
Genital mycotic infections (GMIs) are primarily fungal infections of the urogenital
area (e.g., candidiasis), whereas the urinary tract infections (UTIs) in patients receiving
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SGLT-2is are primarily bladder infections [61]. SGLT-2i-induced glucosuria increases the
risk of GMIs and UTIs, with GMIs occurring at a higher rate than UTIs; these infections
are common in women with a history of genital infection and uncircumcised men (albeit
comparatively less frequent) [12,62]. A meta-analysis of clinical studies showed increased
odds of GMIs with SGLT-2is vs. placebo (odds ratio (OR), 3.87 (95% CI, 3.18–4.71)), whereas
the odds of UTIs were lower than for GMIs (OR, 1.08 (95% CI, 1.00–1.18)) [1].
GMIs usually occur soon after initiation of SGLT-2i treatment, especially in patients
with T2D, and are typically mild in severity [62,63]. They can be managed effectively
with antifungals (either topical or systemic) and by counseling patients about maintaining
adequate personal hygiene to mitigate the risk of infections [63]. An ~10-fold reduction
in the incidence of GMIs may be achieved by regular washing of the urogenital region,
particularly after each void and before going to bed [64]. Furthermore, advising female
patients to wear cotton underwear may reduce the risk of vaginal candidiasis [65]. However,
SGLT-2is should probably be avoided in females with a history of severe, recurrent fungal
infections or in patients with paraparesis, neurogenic bladder, or an indwelling urinary
catheter [39,63]. In general, the physicians agreed that the benefits of SGLT-2is far outweigh
the risks of infection and that they initiate SGLT-2i treatment even in patients with a history
of GMIs or UTIs after a discussion with the patient.
Fournier’s gangrene is a rare serious infection of the genital and perigenital area
(incidence rate, 0.61 cases per 1000 person-years), primarily attributed to poorly controlled
diabetes [66,67]. Although cases of Fournier’s gangrene were reported with SGLT-2i therapy
by the FDA in 2018 [68], they have been attributed to patient-specific risk factors including
poorly controlled diabetes, advanced age, obesity, and alcohol abuse [39,67]. Physician
education about the signs and symptoms of this condition and the importance of patient
monitoring can result in early diagnosis to mitigate the outcome effectively [67].
3.5. Hyperkalemia
There may be a perception that SGLT-2is are associated with an increased risk of
hyperkalemia, based on the findings of a pooled analysis of phase 3 studies, which showed
elevated serum potassium with canagliflozin 300 mg in patients with moderate impairment
of renal function [69]. However, the incidence of hyperkalemia was uncommon in the
canagliflozin CANVAS program [70] and in the canagliflozin CREDENCE study [22].
Moreover, a meta-analysis indicated that canagliflozin, dapagliflozin, and empagliflozin
(with or without concomitant use of mineralocorticoid receptor antagonists [MRAs]) were
not associated with an increased risk of hyperkalemia compared with placebo (hazard ratio
(HR), 0.63 (95% CI, 0.48–0.83), p-heterogeneity = 0.90) [58].
In DAPA-HF, in which 70.1% of patients with HFrEF received MRAs at baseline,
the risks of mild hyperkalemia and moderate-to-severe hyperkalemia were reduced with
dapagliflozin by 14% (HR, 0.86 (95% CI, 0.70–1.05)) and 50% (HR, 0.50 (95% CI, 0.29–0.85)),
respectively, compared with placebo [71]. In DAPA-CKD, the risk of hyperkalemia was
reduced by 13% with dapagliflozin compared with placebo in patients with CKD (HR, 0.87
(95% CI, 0.70–1.09)), irrespective of MRA use at baseline (MRAs prescribed: HR, 0.94 (95%
CI, 0.41–2.20); MRAs not prescribed: HR, 0.87 (95% CI, 0.69–1.10), p-interaction = 0.96);
however, the results were not statistically significant [72]. Similarly, a secondary analysis of
EMPEROR-Reduced demonstrated a non-statistically significant reduction in the risk of
severe hyperkalemia with empagliflozin compared with placebo in patients with HFrEF
(HR, 0.70 (95% CI, 0.47–1.04)), irrespective of MRA use at baseline [73]. The consensus
among the physicians was that hyperkalemia is not a concern with SGLT-2is, even when
used with MRAs.
3.6. Hypoglycemia
Due to the insulin-independent mechanism of action of SGLT-2is, the risk of hypoglycemia with these agents is low in patients with T2D but may increase when SGLT-2is are
used concomitantly with insulin or sulfonylureas (insulin secretagogues) [28,29]. SGLT-2is
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have been studied in combination with other glucose-lowering agents (e.g., dipeptidyl
peptidase-4 inhibitors, glucagon-like peptide 1 agonists, or metformin), and no significant
incidence of hypoglycemia was observed [39]. In CVOTs, the incidence of hypoglycemia
was not increased with empagliflozin [11], canagliflozin [9], or dapagliflozin [10] compared
with placebo, despite approximately half the patients receiving concomitant insulin [39].
In contrast, a pooled analysis of clinical trials of empagliflozin showed an increased hypoglycemia incidence with concomitant sulfonylurea therapy [74]. There is no evidence to
suggest that patients without T2D are at risk of hypoglycemia with SGLT-2is. No patients
without T2D experienced major hypoglycemia in DAPA-HF [75] or severe hypoglycemia
in DAPA-CKD [21].
If a patient with T2D is considered to be at risk of hypoglycemia (e.g., glycated
hemoglobin <7.0–8.0%, history of hypoglycemia, CKD, or advanced age), the dose of
sulfonylurea could be reduced or even stopped, while the insulin dose could be reduced
by 10–20% prior to SGLT-2i initiation, with the frequency of blood glucose monitoring
increased [39,40,75].
3.7. Amputation
An increased risk of amputation, primarily at the toe or metatarsal level, was observed
with canagliflozin vs. placebo in the CANVAS study in patients with T2D and established
CVD or high CVD risk (HR, 1.97 (95% CI, 1.41–2.75)) [9]. Specifically, the risk of amputation
appeared to be the highest in patients with a history of amputation or peripheral artery
disease (PAD) and was not dose-dependent [9,12]. Following CANVAS, a boxed warning
was added to the prescribing information for canagliflozin regarding the risk of lower
extremity amputation in patients with established CVD or high CVD risk, particularly in
those with an increased risk of amputation, including those with PAD, prior amputations,
neuropathy, and diabetic foot ulcers [76]. However, the incidence of amputations was
not increased with canagliflozin in patients with T2D and CKD (CREDENCE [22]) or
in cardiovascular and renal outcomes trials of empagliflozin in patients with T2D and
established CVD (EMPA-REG OUTCOME [77]) or dapagliflozin in patients with T2D and
established CVD or high CVD risk (DECLARE–TIMI 58 [10]), patients with HFrEF with or
without T2D (DAPA-HF [23]), or patients with CKD with or without T2D (DAPA-CKD [21]).
The low risk of amputation with canagliflozin in CREDENCE resulted in the removal
of the boxed warning of this event from the canagliflozin prescribing information [78].
However, physicians should advise patients about proper foot care; monitor at-risk patients
for new pain, skin ulceration, or infections during canagliflozin treatment; and discontinue
canagliflozin if indicated [12,28,39,79]. A similar recommendation has been made for
ertugliflozin due to a potential increased risk of amputation, based on the incidence of
non-traumatic lower limb amputation in clinical trials with ertugliflozin [38].
4. Conclusions
Clinical trial evidence has demonstrated that SGLT-2is provide beneficial effects on CV
and renal outcomes in patients with and without T2D. Irrespective of these benefits, some
of the key barriers to prescribing among physicians are related to understanding the safety
profile of this drug class. However, serious adverse events in SGLT-2i users are relatively
rare. Although some populations may demonstrate increased risk of some adverse events,
most are easily managed and can be mitigated with increased physician education. By
addressing SGLT-2i safety and increasing awareness of the cardiorenal effects, physicians
will more readily integrate SGLT-2is into clinical practice as an option for patients who are
likely to benefit. The use of SGLT-2is in broader patient populations, including patients
without T2D, is increasing in clinical practice. Consequently, additional real-world evidence
of their efficacy and safety will become available in the near future, particularly for patient
populations typically excluded from or underrepresented in clinical trials. This is likely to
enable physicians to further optimize treatment selection and management for individual
patients with indications for SGLT-2i treatment.
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